Dtsch Med Wochenschr 2022; 147(08): 460-469
DOI: 10.1055/a-1520-4184
Dossier

Neues zur Zöliakie

Update on celiac disease
Lukas Poralla
,
Michael Schumann

Die Zöliakie ist eine T-Zell-vermittelte Autoimmunerkrankung. Da Gluten wie ein Trigger dieser Autoimmunreaktion fungiert, entstehen bei der Zöliakie Einblicke in die immunpathologischen Zusammenhänge, die die Entwicklung neuer Therapeutika ermöglichen. Dies und Zusammenfassungen relevanter Empfehlungen der in diesem Jahr erscheinenden, aktualisierten Zöliakie-Leitlinie sind Thema des folgenden Artikels.

Abstract

Celiac disease is a T-cell-mediated autoimmune disorder. It is relevant to us for two very different reasons. Firstly, it has a prevalence of 1 % in the European population. Thus, a huge number of celiac patients remains undiagnosed. Secondly, the celiac trigger, gluten, functions as a “switch”, that has the potential to selectively activate celiac immune pathology, thereby allowing us to uncover previously unknown immune conditions. This again contributes to new celiac treatment modalities that will presumably alleviate the future fate of celiac disease patients. In 2022, the German guidelines for celiac disease are published by the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). We have summarized some of the recommendations published therein.



Publication History

Article published online:
11 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Felber J, Aust D, Baas S. et al. [Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG) regarding coeliac disease, wheat allergy and wheat sensitivity]. Z Gastroenterol 2014; 52: 711-743
  • 2 Laass MW, Schmitz R, Uhlig HH. et al. The prevalence of celiac disease in children and adolescents in Germany. Dtsch Ärztebl Int 2015; 112: 553-560
  • 3 Shan L, Molberg O, Parrot I. et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275-2279
  • 4 Schumann M, Siegmund B, Schulzke JD. et al. Celiac Disease: Role of the Epithelial Barrier. Cell Mol Gastroenterol Hepatol 2017; 3: 150-162
  • 5 du Pre MF, Sollid LM. T-cell and B-cell immunity in celiac disease. Best Pract Res Clin Gastroenterol 2015; 29: 413-423
  • 6 Ivarsson A. The Swedish epidemic of coeliac disease explored using an epidemiological approach – some lessons to be learnt. Best Pract Res Clin Gastroenterol 2005; 19: 425-440
  • 7 Lionetti E, Castellaneta S, Francavilla R. et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med 2014; 371: 1295-1303
  • 8 Vriezinga SL, Auricchio R, Bravi E. et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med 2014; 371: 1304-1315
  • 9 Andren Aronsson C, Lee HS, Koletzko S. et al. Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol Hepatol 2016; 14: 403-409.e3
  • 10 Kagnoff MF, Paterson YJ, Kumar PJ. et al. Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease. Gut 1987; 28: 995-1001
  • 11 Stene LC, Honeyman MC, Hoffenberg EJ. et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006; 101: 2333-2340
  • 12 Bouziat R, Hinterleitner R, Brown JJ. et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 2017; 356: 44-50
  • 13 Leffler D, Schuppan D, Pallav K. et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62: 996-1004
  • 14 Weber M, Wolf N, Branchi F. et al. Results from the German registry for refractory celiac disease. Z Gastroenterol 2021; 59: 944-953
  • 15 Lebwohl B, Kapel RC, Neugut AI. et al. Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointest Endosc 2011; 74: 103-109
  • 16 Werkstetter KJ, Korponay-Szabo IR, Popp A. et al. Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice. Gastroenterology 2017; 153: 924-935
  • 17 Husby S, Koletzko S, Korponay-Szabo I. et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr 2020; 70: 141-156
  • 18 Ruiz-Carnicer A, Garzon-Benavides M, Fombuena B. et al. Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. Am J Clin Nutr 2020; 112: 1240-1251
  • 19 Tangermann P, Branchi F, Itzlinger A. et al. Low Sensitivity of Simtomax Point of Care Test in Detection of Celiac Disease in a Prospective Multicenter Study. Clin Gastroenterol Hepatol 2019; 17: 1780-1787.e5
  • 20 Biagi F, Trotta L, Alfano C. et al. Prevalence and natural history of potential celiac disease in adult patients. Scand J Gastroenterol 2013; 48: 537-542
  • 21 Alhassan E, Yadav A, Kelly CP. et al. Novel Nondietary Therapies for Celiac Disease. Cell Mol Gastroenterol Hepatol 2019; 8: 335-345
  • 22 Lahdeaho ML, Kaukinen K, Laurila K. et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014; 146: 1649-1658
  • 23 Schuppan D, Maki M, Lundin KEA. et al. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. N Engl J Med 2021; 385: 35-45
  • 24 Kelly CP, Murray JA, Leffler DA. et al. TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology 2021; 161: 66-80.e8
  • 25 Malamut G, Cording S, Cerf-Bensussan N. Recent advances in celiac disease and refractory celiac disease. F1000Res 2019; 8: F1000 Faculty Rev-969
  • 26 Daum S, Ipczynski R, Schumann M. et al. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009; 21: 66-70
  • 27 Daum S, Ipczynski R, Heine B. et al. Therapy with budesonide in patients with refractory sprue. Digestion 2006; 73: 60-68
  • 28 Schumann M, Kamel S, Jöhrens K. et al. Zöliakie – Eine Übersicht zur Leitlinie der DGVS. Gastroenterologie up2date 2014; 10 (04) 235-245 DOI: 10.1055/s-0034-1391033.